BRD9 Degrader

About Amphista Therapeutics

Amphista Therapeutics is a private, pre-clinical stage biotech developing a novel class of targeted protein degraders called Targeted Glues®. Its platform utilizes a chemistry-first approach to create molecules with superior drug-like properties, including oral bioavailability and inherent brain penetrance, enabling targeting of a wider range of tissues and indications than traditional TPD methods. The company's lead programs target BRD9 for Acute Myeloid Leukemia and SMARCA2 for Non-Small Cell Lung Cancer, with the goal of addressing high unmet medical need. Amphista's multidisciplinary team, based in the UK's 'golden triangle,' combines deep TPD expertise with computational and AI-driven approaches to advance its pipeline.

Therapeutic Areas

Other Acute Myeloid Leukaemia (AML) Drugs